Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists
暂无分享,去创建一个
Peter Kolb | Andrej Sali | Kenneth A. Jacobson | Adam C. Marko | A. Sali | K. Jacobson | P. Kolb | Zhang-Guo Gao | Zhan-Guo Gao | Khai Phan | Khai Phan
[1] Claudio N. Cavasotto,et al. Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..
[2] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[3] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[4] M. Givertz,et al. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure , 2009, Expert opinion on pharmacotherapy.
[5] Keizo Yoshida,et al. Protective effects of FK453, a potent nonxanthine adenosine A1 receptor antagonist, on glycerol‐induced acute renal failure in rats , 1996 .
[6] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[7] Tudor I. Oprea,et al. WOMBAT: World of Molecular Bioactivity , 2005 .
[8] K. Klotz,et al. 2-Chloro-N6-[3H]cyclopentyladenosine ([3HCCPA) —a high affinity agonist radioligand for A1 adenosine receptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.
[9] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[10] K. Jacobson,et al. 125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.
[11] Barbara Cacciari,et al. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[12] A. Bianucci,et al. QSAR study on a novel series of 8-azaadenine analogues proposed as A1 adenosine receptor antagonists. , 2008, European journal of medicinal chemistry.
[13] G. V. van Westen,et al. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. , 2011, Trends in pharmacological sciences.
[14] B. Fredholm,et al. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[15] J. Irwin,et al. Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.
[16] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[17] Kenneth A Jacobson,et al. Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.
[18] Avner Schlessinger,et al. Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.
[19] Mathias Wawer,et al. Similarity-Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules , 2010, J. Chem. Inf. Model..
[20] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[21] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[22] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[23] S. Rivkees,et al. Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.
[24] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[25] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[26] A. Sali,et al. Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.
[27] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[28] George A. Kaminski,et al. Force Field Validation Using Protein Side Chain Prediction , 2002 .
[29] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[30] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[31] M. Williams,et al. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.
[32] I. Kuntz,et al. Matching chemistry and shape in molecular docking. , 1993, Protein engineering.
[33] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[34] I. Kuntz,et al. Automated docking with grid‐based energy evaluation , 1992 .
[35] Michael M. Mysinger,et al. Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.
[36] J. Ramachandran,et al. Structure and Function of G Protein Coupled Receptors , 1990, Pharmaceutical Research.
[37] M. Lohse,et al. 2-Chloro-N 6 -( 3 H)cyclopentyladenosine (( 3 H)CCPA) - a high affinity agonist radio Iigand for A 1 adenosine receptors , 1989 .
[38] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[39] J M Blaney,et al. A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.
[40] A. Sali,et al. Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.
[41] K. Dickstein,et al. Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure , 2009, Circulation. Heart failure.
[42] M. Givertz,et al. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. , 2009, Expert opinion on pharmacotherapy.
[43] K. Jacobson,et al. New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.
[44] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[45] I. Kuntz,et al. Ligand solvation in molecular docking , 1999, Proteins.
[46] B. Honig,et al. A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.
[47] Peter Kolb,et al. The golden age of GPCR structural biology: any impact on drug design? , 2011, Angewandte Chemie.
[48] Thierry Kogej,et al. Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data , 2009, J. Chem. Inf. Model..
[49] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[50] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.